Unicycive’s kidney drug aims to make life easier for dialysis patients by cutting down the daily pill burden, and it could finally reach the market after a manufacturing setback. The next big moment is the regulator’s decision, but the same manufacturing and rollout risks still hang over the story.Read more

1️⃣ Executive Summary Aurelia Metals Limited has transitioned into a more stable and operationally credible underground producer, with recent developments shifting the investment case toward margin quality and execution consistency. The company is now firmly in an optimisation phase.Read more

Key Takeaways Surging demand in nuclear and infrastructure markets, supported by government policies and technology leadership, drives strong backlog growth and recurring revenue opportunities. Strategic shift toward high-value services and disciplined capital allocation is expanding margins and positioning the company for sustained, outsized growth across core end markets.Read more

Paradigm Biopharmaceuticals is developing an osteoarthritis treatment that looks simpler to make, easier to deliver, and less likely to run into surprise safety and regulator issues than a more complex rival approach. With key trial updates ahead, the company could narrow what the author sees as a big gap between its current market value and what similar programs are being priced at.Read more

A new push from Washington to speed up approvals for big data-centre builds could land right in IREN’s lap, since it’s already lining up large sites in Texas powered by renewable energy. The big question is whether it can execute fast enough to justify today’s high expectations as it shifts from bitcoin mining toward selling computing power for AI.Read more

The AI Operating System for the Real World, Finally Generating Numbers to Match the Vision Palantir Technologies, Inc. (NASDAQ: PLTR) is a Denver, Colorado-based data analytics and artificial intelligence company that builds software platforms for governments and commercial enterprises whose decisions carry consequences large enough to justify the organizational investment that Palantir's products demand.Read more

Beam Therapeutics is betting that a newer, more precise form of gene editing can fix genetic diseases without the DNA damage risks tied to older approaches. Early human results in a liver-targeted program, plus a push to remove harsh chemotherapy from stem cell transplants, could open much larger patient groups—but competition and clinical execution still matter.Read more

Alphabet still makes most of its money from the everyday places people search, watch videos, and tap ads—but now cloud services and built-in AI tools are starting to add a second engine. The big question is whether it can keep that lead while regulators turn up the heat and new AI assistants chip away at how people find information.Read more

TMX Group quietly makes money from the plumbing behind Canada’s stock market, and more of its business now comes from sticky data products that don’t swing as much with day-to-day trading. New clearing services and growth in its European energy and U.S. fund data businesses could deepen that stability, but market slowdowns and tougher competition could still hit results.Read more